Universe Pharmaceuticals Sells 388,000 Shares
Ticker: UPC · Form: 6-K · Filed: Dec 12, 2024 · CIK: 1809616
| Field | Detail |
|---|---|
| Company | Universe Pharmaceuticals INC (UPC) |
| Form Type | 6-K |
| Filed Date | Dec 12, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.28125, $0.79, $15.0 million, $100,000, $15 Million |
| Sentiment | neutral |
Sentiment: neutral
Topics: offering, shares, capital-raise
TL;DR
Universe Pharma selling 388K shares on Dec 6th. Raising cash.
AI Summary
On December 6, 2024, Universe Pharmaceuticals INC entered into a Securities Purchase Agreement to issue and sell 388,000 ordinary shares. The company is a Cayman Islands entity and operates in the pharmaceutical preparations sector.
Why It Matters
This filing indicates Universe Pharmaceuticals is raising capital through a direct offering of its shares, which could impact its financial flexibility and future operations.
Risk Assessment
Risk Level: medium — Share offerings can dilute existing shareholders and signal potential financial needs, but the specific impact depends on the use of proceeds and market conditions.
Key Numbers
- 388,000 — Ordinary Shares (Number of shares Universe Pharmaceuticals INC agreed to issue and sell in a registered direct offering.)
Key Players & Entities
- Universe Pharmaceuticals INC (company) — Filer of the 6-K report and issuer of shares
- December 6, 2024 (date) — Date of the Securities Purchase Agreement
- 388,000 ordinary shares (dollar_amount) — Number of shares to be issued and sold
FAQ
What is the total number of ordinary shares Universe Pharmaceuticals INC agreed to issue and sell?
Universe Pharmaceuticals INC agreed to issue and sell 388,000 ordinary shares.
When was the Securities Purchase Agreement entered into?
The Securities Purchase Agreement was entered into on December 6, 2024.
What type of offering is this for the ordinary shares?
This is a registered direct offering for the ordinary shares.
What is the principal executive office address of Universe Pharmaceuticals INC?
The principal executive office address is 265 Jingjiu Avenue, Jinggangshan Economic and Technological Development Zone, Ji'an, Jiangxi, China, 343100.
Does Universe Pharmaceuticals INC file annual reports under Form 20-F or 40-F?
Universe Pharmaceuticals INC files annual reports under Form 20-F.
Filing Stats: 922 words · 4 min read · ~3 pages · Grade level 14.3 · Accepted 2024-12-12 16:31:10
Key Financial Figures
- $0.28125 — ldquo;Offered Shares”), par value $0.28125 per share (the “ordinary shares&r
- $0.79 — t, or at a combined purchase price of US$0.79 per Pre-funded Warrant (in lieu of one
- $15.0 million — o;). The Company received approximately $15.0 million in gross proceeds from the Offering, be
- $100,000 — Offering. The Company also paid Univest $100,000 for accountable fees and expenses and 1
- $15 Million — Universe Pharmaceuticals INC Announces $15 Million Registered Direct Offering Cautionary
Filing Documents
- ea0224606-6k_universe.htm (6-K) — 19KB
- ea022460601ex5-1_universe.htm (EX-5.1) — 62KB
- ea022460601ex10-1_universe.htm (EX-10.1) — 87KB
- ea022460601ex10-2_universe.htm (EX-10.2) — 191KB
- ea022460601ex10-3_universe.htm (EX-10.3) — 90KB
- ea022460601ex10-4_universe.htm (EX-10.4) — 134KB
- ea022460601ex99-1_universe.htm (EX-99.1) — 8KB
- ex5-1_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-108402.txt ( ) — 596KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Universe Pharmaceuticals INC Date: December 12, 2024 By: /s/ Gang Lai Gang Lai Chief Executive Officer 3